The Calibo platform underwent a thorough evaluation of its technical and procedural controls to ensure alignment with the stringent standards of GxP regulations. This review was meticulously guided by the regulatory specifications outlined in:
- 21 CFR Part 11 Subpart B, which defines the U.S. FDA’s regulations on electronic records.
- EU Annex 11, detailing the European Union’s regulatory requirements.
KPMG performed an in-depth gap analysis to identify areas for enhancement and subsequently presented a report outlining recommended corrective actions. The Calibo team diligently addressed and implemented these suggestions, all of which were subject to successful validation by KPMG.
The Calibo platform fully aligns with the GxP-related controls as delineated by the regulatory standards and guidelines previously mentioned.
Read more